NASDAQ:AXNX Axonics (AXNX) Stock Forecast, Price & News $50.85 +1.68 (+3.42%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$49.16▼$50.9650-Day Range$48.02▼$60.2152-Week Range$46.57▼$79.92Volume638,030 shsAverage Volume648,585 shsMarket Capitalization$2.56 billionP/E RatioN/ADividend YieldN/APrice Target$78.44 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Axonics MarketRank™ ForecastAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside54.3% Upside$78.44 Price TargetShort InterestBearish8.26% of Shares Sold ShortDividend StrengthN/ASustainability-1.38Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$1.34 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.40) to ($0.04) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.13 out of 5 starsMedical Sector386th out of 981 stocksSurgical & Medical Instruments Industry38th out of 97 stocks 3.4 Analyst's Opinion Consensus RatingAxonics has received a consensus rating of Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $78.44, Axonics has a forecasted upside of 54.3% from its current price of $50.85.Amount of Analyst CoverageAxonics has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.26% of the outstanding shares of Axonics have been sold short.Short Interest Ratio / Days to CoverAxonics has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Axonics has recently increased by 0.97%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAxonics does not currently pay a dividend.Dividend GrowthAxonics does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAxonics has received a 59.34% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Incontinence medication", "Implants and prostheses", and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Axonics is -1.38. Previous Next 2.1 News and Social Media Coverage News SentimentAxonics has a news sentiment score of -0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Axonics this week, compared to 3 articles on an average week.Search Interest9 people have searched for AXNX on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.MarketBeat Follows2 people have added Axonics to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Axonics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,344,761.00 in company stock.Percentage Held by InsidersOnly 2.31% of the stock of Axonics is held by insiders.Percentage Held by Institutions97.49% of the stock of Axonics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Axonics are expected to grow in the coming year, from ($0.40) to ($0.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Axonics is -51.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Axonics is -51.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxonics has a P/B Ratio of 4.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Axonics (NASDAQ:AXNX) StockAxonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.Read More Receive AXNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axonics and its competitors with MarketBeat's FREE daily newsletter. Email Address AXNX Stock News HeadlinesMay 31, 2023 | markets.businessinsider.comJefferies Sticks to Its Hold Rating for Axonics Modulation Technologies (AXNX)May 31, 2023 | finance.yahoo.comEven though Axonics (NASDAQ:AXNX) has lost US$173m market cap in last 7 days, shareholders are still up 28% over 3 yearsJune 8, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 23, 2023 | markets.businessinsider.comWhere Axonics Stands With AnalystsMay 23, 2023 | americanbankingnews.comCL King Begins Coverage on Axonics (NASDAQ:AXNX)May 18, 2023 | americanbankingnews.comAxonics, Inc. (NASDAQ:AXNX) Receives $78.88 Consensus PT from BrokeragesMay 16, 2023 | finance.yahoo.comWhat Makes Axonics (AXNX) Unique?May 12, 2023 | seekingalpha.comAxonics: Attractive Strong Growth ProfileJune 8, 2023 | Chaikin Analytics (Ad)Wall Street Veteran: "A New Wave of Crashes Will Rock US Stocks"He called the 2020 crash and 2022 bear market. Now he says the next 90 days will determine your financial life for a decade. It doesn't matter if you have money in stocks right now, or are waiting on the sidelines. The short period we're about to enter changes everything.May 8, 2023 | finance.yahoo.comA Look At The Intrinsic Value Of Axonics, Inc. (NASDAQ:AXNX)May 6, 2023 | americanbankingnews.comAxonics (NASDAQ:AXNX) Price Target Raised to $73.00 at Needham & Company LLCMay 4, 2023 | seekingalpha.comAxonics: Q1 Fall Provides Great Entry PointApril 30, 2023 | americanbankingnews.comAxonics (NASDAQ:AXNX) vs. DexCom (NASDAQ:DXCM) Financial AnalysisApril 30, 2023 | americanbankingnews.comAxonics (AXNX) Scheduled to Post Earnings on MondayApril 26, 2023 | americanbankingnews.comDanny L. Dearen Sells 2,001 Shares of Axonics, Inc. (NASDAQ:AXNX) StockApril 25, 2023 | finance.yahoo.comAxonics to Participate in Upcoming Investor ConferencesApril 24, 2023 | finance.yahoo.comAxonics Acquires Technology to Facilitate Easier and Faster Placement of Implantable Leads for Sacral NeuromodulationApril 23, 2023 | americanbankingnews.comBrokerages Set Axonics, Inc. (NASDAQ:AXNX) PT at $78.63April 19, 2023 | americanbankingnews.comTruist Financial Cuts Axonics (NASDAQ:AXNX) Price Target to $73.00April 17, 2023 | finance.yahoo.comInvestors Interested In Axonics, Inc.'s (NASDAQ:AXNX) RevenuesApril 16, 2023 | americanbankingnews.comMizuho Begins Coverage on Axonics (NASDAQ:AXNX)April 10, 2023 | finance.yahoo.comAxonics to Report First Quarter 2023 Financial Results on May 1April 10, 2023 | americanbankingnews.comHead-To-Head Contrast: Axonics (NASDAQ:AXNX) versus Universal Media Group (OTCMKTS:UMGP)April 6, 2023 | americanbankingnews.comDanny L. Dearen Sells 15,000 Shares of Axonics, Inc. (NASDAQ:AXNX) StockMarch 31, 2023 | americanbankingnews.comAxonics, Inc. (NASDAQ:AXNX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMarch 28, 2023 | americanbankingnews.comAnalyzing Universal Media Group (OTCMKTS:UMGP) & Axonics (NASDAQ:AXNX)March 25, 2023 | americanbankingnews.comAxonics (NASDAQ:AXNX) Stock Rating Upgraded by Needham & Company LLCSee More Headlines AXNX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AXNX Company Calendar Last Earnings5/01/2023Today6/07/2023Next Earnings (Estimated)8/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AXNX CUSIPN/A CIK1603756 Webwww.axonics.com Phone(949) 396-6322Fax949-396-6321Employees610Year FoundedN/APrice Target and Rating Average Stock Price Forecast$78.44 High Stock Price Forecast$90.00 Low Stock Price Forecast$73.00 Forecasted Upside/Downside+54.3%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($0.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,700,000.00 Net Margins-15.64% Pretax Margin-16.42% Return on Equity-8.67% Return on Assets-7.49% Debt Debt-to-Equity RatioN/A Current Ratio7.10 Quick Ratio6.10 Sales & Book Value Annual Sales$273.70 million Price / Sales9.36 Cash FlowN/A Price / Cash FlowN/A Book Value$11.51 per share Price / Book4.42Miscellaneous Outstanding Shares50,380,000Free Float49,220,000Market Cap$2.56 billion OptionableNot Optionable Beta0.40 Key ExecutivesMr. Raymond W. Cohen (Age 64)CEO & Director Comp: $1.71MMr. Danny L. Dearen (Age 60)Pres & CFO Comp: $799.08kMr. Rinda K. Sama (Age 44)Chief Operating Officer Comp: $902.83kDr. John Woock Ph.D. (Age 40)Exec. VP, Chief Marketing & Strategy Officer Comp: $902.83kMr. Alfred J. Ford Jr. (Age 52)Chief Commercial Officer Comp: $902.96kMr. Guangqiang Jiang Ph.D. (Age 49)Chief Technology Officer Mr. Neil BhalodkarVP of Investor RelationsMr. Aaron PettitGen. Counsel & Chief Compliance OfficerMr. Michael V. Williamson Esq. (Age 51)J.D., Sr. VP, Gen. & IP Counsel Dr. Karen L. Noblett M.A.S. (Age 60)M.D., Chief Medical Officer More ExecutivesKey CompetitorsAtriCureNASDAQ:ATRCNuVasiveNASDAQ:NUVAGlaukosNYSE:GKOSAlphatecNASDAQ:ATECiRhythm TechnologiesNASDAQ:IRTCView All CompetitorsInsiders & InstitutionsDanny L DearenSold 7,999 sharesTotal: $395,630.54 ($49.46/share)ProShare Advisors LLCSold 537 shares on 5/26/2023Ownership: 0.011%Royce & Associates LPSold 27,000 shares on 5/23/2023Ownership: 0.115%Ameriprise Financial Inc.Sold 195,458 shares on 5/22/2023Ownership: 0.661%Putnam Investments LLCBought 427 shares on 5/22/2023Ownership: 0.258%View All Insider TransactionsView All Institutional Transactions AXNX Stock - Frequently Asked Questions Should I buy or sell Axonics stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axonics in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AXNX shares. View AXNX analyst ratings or view top-rated stocks. What is Axonics' stock price forecast for 2023? 9 brokerages have issued twelve-month price targets for Axonics' shares. Their AXNX share price forecasts range from $73.00 to $90.00. On average, they predict the company's share price to reach $78.44 in the next twelve months. This suggests a possible upside of 54.3% from the stock's current price. View analysts price targets for AXNX or view top-rated stocks among Wall Street analysts. How have AXNX shares performed in 2023? Axonics' stock was trading at $62.53 at the beginning of 2023. Since then, AXNX stock has decreased by 18.7% and is now trading at $50.85. View the best growth stocks for 2023 here. When is Axonics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 7th 2023. View our AXNX earnings forecast. How were Axonics' earnings last quarter? Axonics, Inc. (NASDAQ:AXNX) released its earnings results on Monday, May, 1st. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.10. The firm earned $70.65 million during the quarter, compared to the consensus estimate of $65.03 million. Axonics had a negative net margin of 15.64% and a negative trailing twelve-month return on equity of 8.67%. The firm's revenue was up 45.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.50) EPS. What ETFs hold Axonics' stock? ETFs with the largest weight of Axonics (NASDAQ:AXNX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Neuberger Berman Disrupters ETF (NBDS), Fidelity Digital Health ETF (FDHT), SPDR S&P Health Care Equipment ETF (XHE), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Nuveen Small Cap Select ETF (NSCS), Principal Healthcare Innovators ETF (BTEC) and Goldman Sachs Future Health Care Equity ETF (GDOC). What guidance has Axonics issued on next quarter's earnings? Axonics issued an update on its FY 2023 earnings guidance on Monday, May, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $348.00 million-$348.00 million, compared to the consensus revenue estimate of $343.77 million. What is Raymond W. Cohen's approval rating as Axonics' CEO? 20 employees have rated Axonics Chief Executive Officer Raymond W. Cohen on Glassdoor.com. Raymond W. Cohen has an approval rating of 89% among the company's employees. 73.0% of employees surveyed would recommend working at Axonics to a friend. What other stocks do shareholders of Axonics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics investors own include Raytheon Technologies (RTX), Oasis Petroleum (OAS), Pfizer (PFE), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT). When did Axonics IPO? (AXNX) raised $100 million in an IPO on Wednesday, October 31st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers. What is Axonics' stock symbol? Axonics trades on the NASDAQ under the ticker symbol "AXNX." Who are Axonics' major shareholders? Axonics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.15%), FMR LLC (5.16%), AXA S.A. (3.32%), Champlain Investment Partners LLC (2.65%), Hood River Capital Management LLC (2.60%) and State Street Corp (2.23%). Insiders that own company stock include Alfred J Ford Jr, Alfred J Ford, Jr, Bakker Juliet Tammenoms, Danny L Dearen, Esteban Lopez, Jane E Kiernan, John Woock, Karen Noblett, Raymond W Cohen, Raymond W Cohen, Rinda Sama and Robert E Mcnamara. View institutional ownership trends. How do I buy shares of Axonics? Shares of AXNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Axonics' stock price today? One share of AXNX stock can currently be purchased for approximately $50.85. How much money does Axonics make? Axonics (NASDAQ:AXNX) has a market capitalization of $2.56 billion and generates $273.70 million in revenue each year. The company earns $-59,700,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. How many employees does Axonics have? The company employs 610 workers across the globe. How can I contact Axonics? Axonics' mailing address is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. The official website for the company is www.axonics.com. The company can be reached via phone at (949) 396-6322, via email at ir@axonics.com, or via fax at 949-396-6321. This page (NASDAQ:AXNX) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axonics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.